Oncocross Announces Strategic Partnership with OmicsAI

Oncocross has recently entered into a new contract for contract research organization (CRO) services in proteomics analysis with OmicsAI. This agreement is considered a significant step forward for Oncocross in advancing its Digital Biobanking (DBB) business and building AI-driven medical data assets. The official announcement of this partnership was made on the 30th, with both companies expressing high expectations for future collaboration.

Key Details and Terms of the Agreement

The scope of this contract includes services such as pre-processing of test samples, protein identification and quantification based on mass spectrometry, data interpretation and statistical analysis, and the provision of result reports and raw data. While the contract amount and specific terms are not disclosed due to business and trade secrets, it is estimated to be over 10% of Oncocross's revenue based on its most recent fiscal year.

• Payment Schedule:
  • 50% Down Payment: July 31, 2026
  • 25% Interim Payment: October 30, 2026
  • 25% Final Payment: December 31, 2026
• Contract Period: July 1, 2026, to December 31, 2026

It's noteworthy that the contract value is calculated based on the planned analysis quantity and may vary depending on the actual number of analyses completed. The board of directors approved the contract on July 30, 2026, with the attendance of outside directors and auditors to ensure transparency.

Oncocross's Financial Status and Market Reaction

As of the fiscal year ending December 2025, Oncocross reported total assets of 29 billion KRW, total liabilities of 15.6 billion KRW, and total equity of 13.4 billion KRW. Recent revenue stood at 400 million KRW, with a net loss of 8.9 billion KRW. This financial standing will serve as a crucial indicator for evaluating the company's growth potential.

Furthermore, Oncocross, listed on the KOSDAQ market on December 18, 2024, operates in the natural science and engineering research and development sector. Its current stock price is 2,730 KRW, showing a 1.68% increase from the previous day. This can be interpreted as a positive market response.

Future Expectations and Outlook

This partnership between Oncocross and OmicsAI is expected to significantly contribute to AI-driven new drug development services. Through their collaboration, both companies aim to build more innovative medical data assets and enhance the efficiency of drug discovery. These efforts are believed to ultimately provide better treatment options for patients.

This new business model, combining AI and biotechnology, holds significant potential to revolutionize the healthcare industry. As we look forward to their future endeavors, it will be important to closely monitor the advancements in this field.